SMG1 and neoplasm: We observed that the treatment with AS1411-SMG1 AsiC and not with AS1411-control AsiC elicits a profound change in the tumor immune microenvironment with a high infiltration of CD8 cytotoxic lymphocytes (Figure 4A), a slight increase of CD4 helper lymphocytes (Figure 4B), and a reduction of Foxp3 Treg lymphocytes (Figure 4C), and the ratio of CD8/Foxp3 lymphocytes was augmented (Figure 4D).